<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03704688</url>
  </required_header>
  <id_info>
    <org_study_id>17-297</org_study_id>
    <nct_id>NCT03704688</nct_id>
  </id_info>
  <brief_title>Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase 1 Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of the combination of ponatinib and&#xD;
      trametinib as well as the most appropriate dosages of the combination.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 9, 2018</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose of Ponatinib and Trametinib</measure>
    <time_frame>maximum of 18 months</time_frame>
    <description>In the Phase I portion of the study, a standard 3+3 design will be used to find the maximum tolerated dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>1 year</time_frame>
    <description>In the Phase II portion of the study, RECIST criteria 1.1 will evaluate the overall response rate.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>KRAS Gene Mutation</condition>
  <arm_group>
    <arm_group_label>Phase I: Dose Level -3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trametinib 0.5mg PO q daily Ponatinib 15mg PO q daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I: Dose Level -2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trametinib 1.0 mg PO q daily Ponatinib 15mg PO q daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I: Dose Level -1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trametinib 1.5 mg PO q daily 15mg PO q daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I: Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trametinib 2 mg PO q daily Ponatinib 15mg PO q daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I: Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trametinib 2 mg PO q daily Ponatinib 30mg PO q daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maximum tolerated dose as established in Phase I portion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib 0.5 mg</intervention_name>
    <description>0.5mg PO q daily</description>
    <arm_group_label>Phase I: Dose Level -3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib 1 MG</intervention_name>
    <description>1.0 mg PO q daily</description>
    <arm_group_label>Phase I: Dose Level -2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib 1.5 MG</intervention_name>
    <description>1.5mg PO q daily</description>
    <arm_group_label>Phase I: Dose Level -1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib 2 mg</intervention_name>
    <description>2 mg PO q daily</description>
    <arm_group_label>Phase I: Dose Level 1</arm_group_label>
    <arm_group_label>Phase I: Dose Level 2</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ponatinib 15 MG</intervention_name>
    <description>15mg PO q daily</description>
    <arm_group_label>Phase I: Dose Level -1</arm_group_label>
    <arm_group_label>Phase I: Dose Level -2</arm_group_label>
    <arm_group_label>Phase I: Dose Level -3</arm_group_label>
    <arm_group_label>Phase I: Dose Level 1</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ponatinib 30 MG</intervention_name>
    <description>30mg PO q daily</description>
    <arm_group_label>Phase I: Dose Level 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically proven diagnosis of advanced lung adenocarcinoma&#xD;
&#xD;
          -  KRAS mutation&#xD;
&#xD;
          -  Radiographic progression following prior treatment with platinum doublet chemotherapy&#xD;
             and prior treatment with a PD-1/L1 inhibitor. Patients who are deemed not eligible for&#xD;
             therapy with a PD-1/L1 inhibitor by their treating physician will also be eligible.&#xD;
&#xD;
          -  Able to take oral medications&#xD;
&#xD;
          -  Measurable disease as per RECIST 1.1. Previously irradiated sites of tumor may be&#xD;
             considered measurable if there is radiographic progression at the site subsequent to&#xD;
             the time of completing radiation.&#xD;
&#xD;
          -  Karnofsky performance status (KPS) ≥ 70%&#xD;
&#xD;
          -  Age &gt;18 years old&#xD;
&#xD;
          -  Adequate organ function:&#xD;
&#xD;
               -  AST, ALT ≤ 2.5 x ULN - Total bilirubin ≤ 1.5 x ULN -Albumin ≥ 2.5g/dL&#xD;
&#xD;
               -  Creatinine &lt; 1.5 x ULN OR calculated creatinine clearance ≥ 50mL/min&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1,200 cells/mm^3&#xD;
&#xD;
               -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
               -  Platelets ≥ 100,000/mm^3&#xD;
&#xD;
               -  Amylase and lipase within normal limits (amylase ≤ 100, lipase ≤ 78)&#xD;
&#xD;
          -  Female patients who:&#xD;
&#xD;
               -  Are postmenopausal for at least 1 year before the screening visit, OR&#xD;
&#xD;
               -  Are surgically sterile, OR&#xD;
&#xD;
               -  If they are of childbearing potential, agree to practice 2 effective methods of&#xD;
                  contraception, at the same time, from the time of signing the informed consent&#xD;
                  through 30 days after the last dose of study drug, or agree to completely abstain&#xD;
                  from heterosexual intercourse&#xD;
&#xD;
          -  Male patients, even if surgically sterilized (i.e., status post-vasectomy), who:&#xD;
&#xD;
               -  Agree to practice effective barrier contraception during the entire study&#xD;
                  treatment period and through 30 days after the last dose of study drug, or&#xD;
&#xD;
               -  Agree to completely abstain from heterosexual intercourse&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with symptomatic brain metastasis requiring escalating doses of steroids&#xD;
&#xD;
          -  Patients with grade 2 or greater diarrhea prior to study initiation despite maximal&#xD;
             medical management&#xD;
&#xD;
          -  History of acute pancreatitis within 1 year of study entry or history of chronic&#xD;
             pancreatitis&#xD;
&#xD;
          -  History of or ongoing alcohol abuse that, in the opinion of the Investigator, would&#xD;
             compromise compliance or impart excess risks associated with study participation.&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Any type of systemic therapy (chemotherapy or experimental drugs) within 2 weeks of&#xD;
             starting treatment on protocol&#xD;
&#xD;
          -  Patients who have received prior treatment with MEK inhibitor&#xD;
&#xD;
          -  A history of clinically significant interstitial lung disease or pneumonitis&#xD;
&#xD;
          -  Significant uncontrolled or active cardiovascular disease, specifically including, but&#xD;
             not restricted to: History of clinically significant (as determined by the treating&#xD;
             physician) atrial arrhythmia; or any ventricular arrhythmia, History of congenital&#xD;
             long QT syndrome., Abnormal QTc (≥ 450 msec in males and ≥ 470 msec in females),&#xD;
             Ejection fraction ≤ 50% as assessed by echocardiogram.&#xD;
&#xD;
          -  History of arterial thrombotic disease, specifically including, but not restricted to:&#xD;
             Myocardial infarction or unstable angina, cerebrovascular event (CVA) or transient&#xD;
             ischemic attack (TIA), Peripheral vascular disease or claudication.&#xD;
&#xD;
          -  Uncontrolled hypertension (Diastolic blood pressure &gt; 100 mmHg; Systolic blood&#xD;
             pressure &gt; 150 mmHg).&#xD;
&#xD;
          -  History of venous thromboembolism (e.g. deep venous thrombosis or pulmonary embolism)&#xD;
             within 6 months of study entry. Note: Participants enrolled after this window must be&#xD;
             on appropriate therapeutic anticoagulation.&#xD;
&#xD;
          -  History of central serous retinopathy or retinal vein occlusion&#xD;
&#xD;
          -  Patients with baseline risk factors for central serous retinopathy or retinal vein&#xD;
             occlusion such as evidence of new optic disc cupping, evidence of new visual field&#xD;
             defects, and intraocular pressure &gt;21 mmHg are excluded from the trial&#xD;
&#xD;
          -  History of prior malignancy within 2 years that requires treatment. Patients who are&#xD;
             considered NED from a malignancy may be considered on a case by case basis.&#xD;
&#xD;
          -  Any other condition that, in the opinion of the investigator, may compromise the&#xD;
             safety, compliance of the patient, or would preclude the patient from successful&#xD;
             completion of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathryn Arbour, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities)</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Monmouth (Limited Protocol Activities)</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen (Limited Protocol Activities)</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center @ Suffolk (Limited protocol activity)</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester (Limited Protocol Activities)</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan - Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau (Limited protocol activity)</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 10, 2018</study_first_submitted>
  <study_first_submitted_qc>October 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2018</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>trametinib</keyword>
  <keyword>Ponatinib</keyword>
  <keyword>KRAS Mutant Advanced Non-Small Cell Lung Cancer</keyword>
  <keyword>17-297</keyword>
  <keyword>Memorial Sloan Kettering Cancer Center</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trametinib</mesh_term>
    <mesh_term>Ponatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

